Creso Pharma’s Mernova receives initial purchase order

By Trevor Hoey. Published at Sep 21, 2020, in ASX Biotechs

Creso Pharma Limited’s (ASX:CPH; FRA:1X8) wholly-owned subsidiary, Mernova Medicinal Inc. (Mernova), a Licensed Producer of cannabis products with its operations based in Nova Scotia, Canada, has received an initial purchase order (PO) valued at C$180,000.

The order was received from the Nova Scotia Liquor Corporation (NSLC) for the purchase of two of its premium strains, HPG13 and Lemon Haze.

The NSLC is operated by the Nova Scotia Provincial government and is the sole distributor of retail cannabis in Nova Scotia.

This important milestone marks the imminent launch of Mernova’s Ritual Green brand of high-quality cannabis products into Canada’s rapidly growing recreational markets.

Entering Canada’s retail markets diversifies Mernova’s revenue streams and builds on an established and growing wholesale product sales pipeline.

Ritual Green to be sold through NSLC stores and e-commerce platforms

Mernova’s retail recreational cannabis products will be launched under the brand name ‘Ritual Green’ and will initially be sold through the Nova Scotia Liquor Corporation’s (NSLC) stores and e-commerce platform.

The first product available to recreational customers will be Mernova’s high-quality dried flower in its natural form.

Additional high-quality products will be added to the product line as they become available.

The Ritual Green HPG13 product is illustrated below.

Further recreational and medicinal opportunities for Mernova

Highlighting the significance of this development in terms of building a strong brand in the group’s home province, Mernova’s managing director Jack Yu said, “Receiving this initial PO is the first step to Mernova establishing itself as a trusted supplier of high-quality, locally grown, artisanal cannabis products to the NSLC.

“To meet the supply chain demands of the NSLC and other provincial purchasers, we are adjusting our grow scheduling, while simultaneously ramping up production of our highest quality strains.

“We plan on taking full advantage of this opportunity to build our brand and brand loyalty, in our home province of Nova Scotia and I look forward to providing further updates in the near-term.”

Creso Pharma’s management said that it will continue to provide regular updates on retail and wholesale sales, as well as expansion opportunities available to Mernova as referred to by Yu.

Mernova is also making considerable progress towards securing EU (European Union) Good Manufacturing Practice (GMP) certification, a development that could be a significant share price catalyst for Creso Pharma.

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Australian ASX Small Cap stocks | Why Finfeed.com is Australia’s leading small cap publication

Founded seven years ago, Finfeed.com is Australia’s leading and longest standing website for investor and finance news, education and expert opinion.

Published by StocksDigital, Finfeed was created to report daily on the comings and goings of ASX listed stocks in the small cap market.

As the first digital publication dedicated specifically to this space, Finfeed soon became the most trusted publication in the market, quickly garnering over two million page views – a number that continues to rise.

Finfeed.com provides its readers with informative articles that tackle the latest in market moving #ASX small cap news, plus exclusive content you won’t find anywhere else. It is aimed at those with an interest in investing, market education, company performance, start-ups and much more.

Finfeed.com is the only media organisation operating under the strength of a Financial Services License and is backed by leading journalists and analysts all with brands of their own.

The website aims to inform, educate and entertain with content that drills down into the heart of financial matters.

Finfeed is a leading source of investor and market information, with everything investors need to know about how to invest written in a way that anyone can understand. 

Over the years, the website has expanded beyond exclusively reporting on small caps, to profile Australia’s leading ASX listed small, mid and large caps as well as some of the country’s most successful CEOs and business leaders to find out what makes them tick.

Every day you will find fresh content covering:

Fast Facts

Over 4,000 articles published

Over 2.3 Million Page Views and counting

Over 10,000 followers on social media

Subscriber list growing by 2% monthly

Thanks for subscribing!

X